The widely disseminated surveillance case definition of the eosinophilia-myalgia syndrome (EMS) recommended by the Centers for Disease Control in 1989 has never been validated by an appropriate challenge and has commonly been used for unintended purposes. To accurately classify patients for clinical and epidemiologic studies and to properly diagnose individual patients, an acceptable set of criteria must be established. In determining which combination of clinical and laboratory manifestations should be properly included in criteria for EMS the following elements should be considered: (1) the presence of a well delineated, documented acute episode with characteristic symptoms, signs, and laboratory abnormalities; (2) the presence of characteristic histopathological abnormalities; (3) the presence of objective evidence for involvement of the most commonly affected major organs: skin, muscle, nerve, and/or lung; and (4) the absence of premorbidities or comorbidities that could explain the components of illness on which the diagnosis is based. A preliminary set of criteria is proposed in this paper. This model requires further scrutiny, revision, and testing.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Eosinophilia-myalgia syndrome induced by excessive L-tryptophan intake from cashew nuts.
Cent Eur J Med
August 2014
1University Hospital Center Zagreb, 10000 Zagreb, Croatia.
Eosinophilia is characterized by more than 0.5 × 10 eosinophils per liter in the full blood count. A wide range of conditions, from asthma to parasitic infections, autoimmune diseases, and certain forms of cancer, have been known to trigger abnormally high amount of eosinophils.
View Article and Find Full Text PDFSafety of 5-hydroxy-L-tryptophan.
Toxicol Lett
April 2004
ISSI Laboratories Inc., 515 Blue Ridge Avenue, Piscataway, NJ 08854, USA.
5-Hydroxy-L-tryptophan (5-HTP) is the immediate precursor in the biosynthesis of 5-hydroxy-tryptamine (5-HT; serotonin) from the essential amino acid L-tryptophan (L-Trp). The use of L-Trp as a dietary supplement was discontinued in 1989 due to an outbreak of eosinophilia-myalgia syndrome (EMS) that was traced to a contaminated synthetic L-Trp from a single manufacturer. 5-HTP has since become a popular dietary supplement in lieu of the removal of L-Trp from the market.
View Article and Find Full Text PDFDiagnostic bias in clinical decision making: an example of L-tryptophan and the diagnosis of eosinophilia-myalgia syndrome.
J Rheumatol
December 1996
Yale University School of Medicine, New Haven, Connecticut, USA.
Objective: Eosinophilia-myalgia syndrome (EMS) has been defined as the clinical presentation of eosinophilia, severe myalgia, and the exclusion of other infectious/malignant illnesses. Since the case definition does not require exposure to L-tryptophan (LT), diagnostic bias would occur if a physician's decision to diagnose EMS were influenced by knowledge of LT use.
Methods: A random sample of 813 physicians practising in the United States and Canada was obtained.
Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
J Rheumatol Suppl
October 1996
Department of Medicine and Epidemiology, Yale University School of Medicine, New Haven, Connecticut 06520-8056, USA.
When investigating the cause of a chronic disease, epidemiologists are forced to substitute observational, nonexperimental methods such as cohort or case-control studies for the scientifically preferred "gold standard," the randomized controlled trial. Because neither cohort nor case-control studies are done under experimental conditions, the results may not accurately reflect those that would be found in a randomized experiment. Before the results of epidemiologic research can be used for inference regarding a cause of disease, it is necessary to examine the design and conduct of such studies to ensure their results could not have been distorted by potential sources of bias.
View Article and Find Full Text PDFA diagnostic algorithm for distinguishing the eosinophilia-myalgia syndrome from fibromyalgia and chronic myofascial pain.
J Rheumatol Suppl
October 1996
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Objective: To develop a diagnostic algorithm for the eosinophilia-myalgia syndrome (EMS) that complements the existing case definition.
Methods: We conducted a retrospective study using data on 59 clinical and laboratory variables from a consecutive referral cohort of 91 patients with EMS meeting the Centers for Disease Control and Prevention case definition. Age and sex matched controls included 93 patients with fibromyalgia and 99 patients with chronic myofascial pain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!